期刊
TRENDS IN MOLECULAR MEDICINE
卷 12, 期 2, 页码 65-75出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2005.12.001
关键词
-
资金
- NIMH NIH HHS [MH51699, MH01723] Funding Source: Medline
- NINDS NIH HHS [NS048478] Funding Source: Medline
The two lysophospholipids (LPs) lysophosphatidic acid and sphingosine 1-phosphate (S1P) regulate diverse biological processes. Over the past decade, it has become clear that medically relevant LP activities are mediated by specific G protein-coupled receptors, implicating them in the etiology of a growing number of disorders. A new class of LP agonists shows promise for drug therapy: the experimental drug FTY720 is phosphorylated in vivo to produce a potent S1P receptor agonist (FTY720-P) and is currently in Phase III clinical trials for kidney transplantation and Phase II for multiple sclerosis. Recent genetic and pharmacological studies on LP signaling in animal disease models have identified new areas in which interventions in LP signaling might provide novel therapeutic approaches for the treatment of human diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据